Biotech Values

[DewDiligence]

DYAI—(+33%)—climbs on the COVID-19 bandwagon:

https://finance.yahoo.com/news/dyadic-frederick-national-laboratory-develop-123000773.html

Dyadic International, Inc., a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it was selected by the Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates which will be utilized by the Vaccine Research Center (VRC) part of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health.

It's getting a little late for these kinds of pops, but there will undoubtedly be a few more of them.